Evidence map›Paper›PMID 40038109›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025

Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients.

Qing Zhang, Wenxue Gao, Xiaojuan Xu, Ran Cui, Bin Su

Abstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qing Zhang *Department of Transfusion, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China.
Wenxue Gao *Clinical Research Unit, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Xiaojuan XuKangqiao Community Health Service Center, Pudong New Area, Shanghai, 201906, China.
Ran CuiDepartment of Endocrinology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China. cuiran1172@163.com.
Bin SuDepartment of Transfusion, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, 301 Middle Yanchang Road, Shanghai, 200072, China. 1400801@tongji.edu.cn.ORCID http://orcid.org/0009-0000-0929-3426

Funding

Clinical research project of Shanghai Tenth People's Hospital of Tongji University YNCR2C001Research-oriented Physician of Shanghai Tenth People's Hospital 2023YJXYSC004Science and Technology Commission of Shanghai Chongming District CKY2021-20Science and Technology Commission of Shanghai Municipality 22Y11904900Shanghai Hospital Development Center Foundation SHDC2022CRS033Teaching research project of Shanghai Tenth People's Hospital of Tongji University 2021-A-2the National Natural Science Foundation hospital cultivation project of Shanghai Tenth People's Hospital of Tongji University DSYY202217
6 · The paper itself

Abstract

This study examined the link between baseline CTX levels and zoledronic acid's effectiveness in boosting bone density in osteoporosis patients. Among 472 Chinese patients, higher initial CTX levels correlated with greater lumbar spine bone density improvement after treatment. However, no such correlation was found for hip or femoral neck bones. This suggests CTX levels may aid in treatment selection for lumbar spine, though further research is needed. The findings have clinical implications for optimizing osteoporosis treatment. PURPOSE: To elucidate the correlation between baseline CTX levels and the therapeutic efficacy of zoledronic acid in augmenting bone mineral density (BMD) among individuals with osteoporosis.

methodsThis study studied patients diagnosed with primary osteoporosis who were hospitalized at least twice and received annual zoledronic acid therapy. Patients were stratified into three groups based on their initial CTX levels prior to zoledronic acid administration. ANOVA was employed to compare BMD alterations across the groups. Generalized estimating equations (GEE) were utilized to analyze the relationship between baseline CTX levels and subsequent BMD changes post-zoledronic acid treatment. Statistical analyses were conducted using SPSS version 26.0.

resultsA total of 472 patients were evaluated and categorized into three cohorts according to their initial CTX levels, arranged in ascending order. Notably, group 3, characterized by the highest initial CTX levels, demonstrated a significantly more pronounced increase in lumbar spine BMD compared to the other two groups. Specifically, when group 1 served as the reference, group 3 exhibited a 0.4-unit elevation in lumbar spine T-score. Conversely, no discernible relationship was observed between baseline CTX levels and BMD changes in the hip or femoral neck following zoledronic acid treatment.

conclusionsOur findings among a Chinese population indicate that elevated CTX levels, particularly exceeding 0.480 ng/ml, are notably associated with enhanced therapeutic efficacy of zoledronic acid in boosting lumbar spine BMD. However, this correlation appears less robust with respect to improvements in hip and femoral neck BMD.

Indexed as

Bone DensityBone Density Conservation AgentsCollagen Type IOsteoporosisPeptidesZoledronic AcidAbsorptiometry, PhotonAgedAged, 80 and overBiomarkersEast Asian PeopleFemaleFemur NeckHumansLumbar VertebraeMaleBiomarkersBone Density Conservation AgentsCollagen Type Icollagen type I trimeric cross-linked peptidePeptidesZoledronic AcidBisphosphonateBone mineral densityFractureOsteoporosisZoledronic acid

Identifiers

PMID40038109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.